NCT06009029View on ClinicalTrials.gov

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Locally Advanced Pancreatic Cancer
Interventions
RADIATION

Stereotactic body radiation(SBRT)

"SBRT: 7-10 Gy/F, 5 doses~Zimberelimab: 240mg d1 iv Q21D, within 7 days after SBRT completion. Receiving a minimum of six cycles of treatment, or disease progression or intolerable toxic side effects."

DRUG

Zimberelimab (GLS-010)

Zimberelimab (GLS-010),240mg d1 iv Q21D

All Listed Sponsors
lead

Peking University Third Hospital

OTHER

NCT06009029 - SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) | Biotech Hunter | Biotech Hunter